Rates for Completion of Intercourse Increase Substantially
Tokyo, Japan and San Francisco – October 6, 2009. A new research study published in the The Journal of Sexual Medicine shows that Vardenafil, a second-generation phosphodiesterase type 5 (PDE5) inhibitor, significantly improved success rates in the maintenance of an erection sufficient for completion of intercourse in diabetic men. The study, performed by researchers from both Japan and the United States, suggests that Vardenafil may be used as a treatment for erectile dysfunction where there are multiple underlying factors causing ED, as is the case with diabetes mellitus. The study was led by Sadao Kamidono of the Toho University School of Medicine in Tokyo, Japan. Dr. Paul Turek, director of The Turek Clinic in San Francisco, was a co-researcher on the project.
This study makes clear that Vardenafil can be effective for completing intercourse even in difficult-to-treat ED patients. ”
– Dr. Paul Turek
Erectile dysfunction is a common complication of diabetes. More than 50% of men with diabetes mellitus develop ED within ten years of being diagnosed, and the prevalence of ED increases with age, duration of the diseases, poor glycemic control, and complications of diabetes such as vascular disease. ED in diabetic men has also traditionally been more difficult to treat due to the multiple factors involved in diabetes-related ED. 10 – 20 mg of Vardenafil has previously been shown to improve erectile function in men with both diabetes and ED, but it had not been determined whether it would lead to improved success rates in completion of intercourse.
The researchers used a double-blind study to evaluate 778 Japanese men aged 20-64 who had suffered erectile dysfunction for greater than three years who also suffered from diabetes mellitus. The patients were instructed to take Vardenafil (or placebo tablets) one hour before initiating sexual intercourse. Post intercourse, the patients were required to fill out a Sexual Encounter Profile indicating whether they had completed intercourse successfully.
The results of the study showed that men who took Vardenafil between 15 minutes and 2 hours before initiating intercourse had substantially improved sexual completion rates. For example, men who took Vardenafil from 15-30 minutes before engaging in intercourse had a 71.5% intercourse completion rate, vs 6.2% for men on placebo.
This “first-dose” success is important. ED often leads to impairment of confidence and self-esteem in men, and can substantially reduce the quality of life for both members of a couple in an intimate relationship. Vardenafil’s reliability and efficacy should allow men suffering from ED to confidently enter into intercourse with their partner, which reduces stress on both members of the couple and allows the sexual experience to be more relaxed and pleasurable.
About The Turek Clinic
The Turek Clinic is a next-generation men’s healthcare medical practice specializing in issues facing reproductive age men, including male infertility, erectile dysfunction, vasectomy, vasectomy reversal, varicocele repair, and other minimally invasive procedures. The practice was founded in 2008 by Dr. Paul Turek, a pioneer in men’s reproductive health and former endowed chair professor at the University of California San Francisco. Dr. Turek’s work combines innovative and cutting edge techniques with the wisdom of old-world medicine to treat and solve men’s health issues. For more information visit www.TheTurekClinic.com.